The number of COVID-19 studies is quickly increasing day by day. However, several studies have been suspended. Among these, an update on Tocilizumab comes from Italian researchers that had started a randomised controlled trial. Tocilizumab is a monoclonal antibody against the Interleukin-6 receptor, involved in the immune storm developed during the COVID-19 infection and responsible for damage to the lungs and other organs.
The study, sponsored by Azienda USL-IRCCS of Reggio Emilia, aimed to evaluate whether early administration of Tocilizumab compared to late administration can reduce the number of patients with COVID-19 pneumonia who require mechanical ventilation.
The researchers reported that the study ended early, just after the enrolment of 126 patients (one third of the expected cases), as it showed no benefit either in terms of aggravation (entry into intensive care) or in terms of survival.
Agenzia Italiana del Farmaco (AIFA) clarified that although Tocilizumab has no efficacy in all patients with COVID-19 pneumonia, it is possible that selected subgroups of patients may have a better response to the drug. This will require further analysis on a broader population or specific studies to assess this research hypothesis.
You can find more information about the studies on COVID-19 by visiting our dedicated page, regularly updated, which collects detailed data on these studies, including those on Tocilizumab.
There are currently 54 studies evaluating the efficacy and safety of Tocilizumab, administered alone or in combination with other drugs.
Visit our page and do not miss any further update!